Sierra Oncology, Inc.
BIOMARKERS AND PATIENT SELECTION STRATEGIES

Abstract:

Herein disclosed are methods for treatment of cancer and methods for patient selection for administration of cancer treatment regimens comprising inhibitors of checkpoint kinase 1 (Chk1). In particular, disclosed herein are methods for identification of patients with tumors harboring genetic alterations that confer sensitivity to Chk1 inhibition.